drugset / Trial / NCT03649321
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
Phase 1/2
Terminated
9 enrolled
University of Texas Southwestern Medical Center
BerGenBio ASA · collabTranslational Genomics Research Institute · collabTriligent International · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Determine the overall response rate (ORR) of bemcentinib plus chemotherapy (nab-paclitaxel/gemcitabine) in patients with metastatic pancreatic adenocarcinoma.
Timeline
- Start
- 2019-01-03
- Primary completion
- 2022-06-27
- Completion
- 2022-06-27
Outcome
Outcome not reported
Stopped (Business): “Funding was terminated early because research interests were going in a different direction.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemcentinib | Small molecule | 200 mg | Oral |
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 800 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Nab-paclitaxel | Small molecule | 100 mg/m2 | — |
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | — |